Alvotech And Teva To Miss US Adalimumab Launch After Further FDA Setback
Firms Get Another CRL Over AVT02 High-Concentration Interchangeable Biosimilar
• By David Wallace
Teva and Alvotech will not be able to join the group launching adalimumab biosimilars at the start of July • Source: Shutterstock 
